Anti-Heparanase Aptamers as Potential Diagnostic and Therapeutic Agents for Oral Cancer by Simmons, Suzanne C. et al.
Anti-Heparanase Aptamers as Potential Diagnostic and
Therapeutic Agents for Oral Cancer
Suzanne C. Simmons1., Hannaleena Ja¨msa¨4,5., Dilson Silva2, Celia M. Cortez2, Edward A. McKenzie3,
Carolina C. Bitu4,5, Sirpa Salo4, Sini Nurmenniemi4, Pia Nyberg4,5, Juha Risteli6, Carlos E. B. deAlmeida1,7,
Paul E. C. Brenchley8, Tuula Salo4,5,9,10*, Sotiris Missailidis11*
1Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, United Kingdom, 2 Institute of Mathematics and Statistics, Rio de Janeiro State
University, Rio de Janeiro, Brazil, 3Manchester Institute of Biotechnology, University of Manchester, Manchester, United Kingdom, 4Department of Diagnostics and Oral
Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland, 5Medical Research Center and Oulu University Hospital, Oulu, Finland, 6 Institute of Diagnostics,
Department of Clinical Chemistry, University of Oulu, Oulu, Finland, 7 Laborato´rio de Radiobiologia, Instituto de Radioprotec¸a˜o e Dosimetria, Rio de Janeiro, Brazil, 8 Renal
Research Group, University of Manchester, Manchester, United Kingdom, 9Graduate Program in Estomatopatologia, Piracicaba Dental School, University of Campinas,
Piracicaba, Sa˜o Paulo, Brazil, 10 Institute of Dentistry, University of Helsinki, Helsinki, Finland, 11 Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de
Janeiro, Rio de Janeiro, Brazil
Abstract
Heparanase is an endoglycosidase enzyme present in activated leucocytes, mast cells, placental tissue, neutrophils and
macrophages, and is involved in tumour metastasis and tissue invasion. It presents a potential target for cancer therapies
and various molecules have been developed in an attempt to inhibit the enzymatic action of heparanase. In an attempt to
develop a novel therapeutic with an associated diagnostic assay, we have previously described high affinity aptamers
selected against heparanase. In this work, we demonstrated that these anti-heparanase aptamers are capable of inhibiting
tissue invasion of tumour cells associated with oral cancer and verified that such inhibition is due to inhibition of the
enzyme and not due to other potentially cytotoxic effects of the aptamers. Furthermore, we have identified a short 30 bases
aptamer as a potential candidate for further studies, as this showed a higher ability to inhibit tissue invasion than its longer
counterpart, as well as a reduced potential for complex formation with other non-specific serum proteins. Finally, the
aptamer was found to be stable and therefore suitable for use in human models, as it showed no degradation in the
presence of human serum, making it a potential candidate for both diagnostic and therapeutic use.
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Introduction
Heparanase is a b-1,4-endoglycosidase enzyme [1] that
participates in extracellular matrix (ECM) degradation and
remodeling [1]. The heparanase gene was first cloned in 1999
by the Vlodavsky and Parish groups in the seminal back to back
Nature medicine papers [2,3].
The nascent polypeptide is a 543 amino acid pre-proenzyme,
which after removal of the signal peptide sequence in the
endoplasmic reticulum, undergoes proteolytic processing in late
endosomes/lysosomes by cathepsin-L like proteases [4] at sites
Glu109-Ser110 and Gln157-Lys158, yielding a N-terminal 8 kDa
polypeptide, a C-terminal 50 kDa polypeptide and between them
a 6 kDa linker polypeptide [3]. The 50 and 8 kDa polypeptides
associate to form a heterodimeric active enzyme, whilst the 6 kDa
linker is excised and degraded [5,6].
Heparanase activity is associated with activated leukocytes, mast
cells, placental tissue and macrophages and the enzyme is secreted
by activated CD4 + T cells [7,8,9], platelets [3], neutrophils and
metastatic cells [10]. Upon secretion of heparanase from
metastatic tumour cells, the enzyme hydrolyses the glycosidic
bonds of heparan sulfate chains attached to proteoglycans to a
product of 10–20 sugar units in length [11], leading to penetration
of the endothelial cells of blood vessels and target organs by the
tumor cell. Liberation of bound cytokines and growth factors
sequestered by heparan sulfate chains in tissues [12] further
facilitates growth of the tumour and promotes angiogenesis and
proliferation of secondary tumours [13]. Levels of heparanase
expression in tumour cells correlate with their metastatic potential;
elevated levels of heparanase mRNA and protein have been found
in cancer patients who show significantly shorter postoperative
survival times than patients whose heparanase levels are normal
[13,14].
Heparanase upregulation in cancer cells from myeloma,
lymphoblastoid and breast cancer reflects in augmentation of
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exosome secretion with an enhanced content of syndecan-1,
VEGF and HGF whose roles are closely related to tumor
aggressiveness [15]. In addition to its function in cancer
progression, heparanase enzyme also plays a major role in
inflammation per se and carcinogenesis related to inflammatory
process [16]. The enzyme has been detected in a variety of
immune cells including T and B cells, macrophages, neutrophils
and mast cells. It has been shown to mediate extravasation
through the endothelial barrier via the remodeling of ECM
heparan sulfate, which then allows trafficking to the sites of
inflammation [10,17,18]. Heparanase expression has been linked
to tumorigenesis in a number of different cancers, for example,
acute myeloid leukaemia [19], bladder, brain [20], breast [21],
colon [22], gastric [23], oesophageal [24], oral [25], pancreatic
[14], and cervical cancer [26], suggesting that it may be a suitable
target for drug therapy. Currently available inhibitors of hepar-
anase include neutralizing antibodies [27], peptides [28] and small
molecules [29,30].
A number of modified heparins and sulphated oligosaccharides
have also been shown to be potent heparanase inhibitors with
promising anti-tumour activities and have now advanced to the
clinical testing stages. Examples of these include SST0001, M402,
PI-88 and PG545. SST0001 is a fully N-acetylated modified
heparin which lacks anti-coagulant activity and shown to be a
selective heparanase inhibitor. It is currently in Phase I/II clinical
trials for treatment of myeloma patients. M402 is an N-sulfated
modified heparin that binds a wider range of growth factors
compared to SST0001. This has progressed to Phase I/II clinical
trials as a combination therapy with the chemotherapy agent
gemcitabine for the treatment of metastatic pancreatic cancer. PI-
88 is a sulphated polysaccharide with potent anti-angiogenic and
anti-metastatic activity and with reduced unwanted anticoagulant
activity. It has reached Phase III clinical trials for post-resection
hepatocellular carcinoma. PG545 is a tetrasaccharide which has
superior pharmacokinetic properties due to its high degree of
lipophilicity. It has shown potent anti-tumour activity in PI88
resistant models, however, Phase I clinical trials in late 2010 were
abandoned due to unexpected injection site reactions [31].
Aptamers are short DNA or RNA oligonucleotides developed
for diagnostic and therapeutic use that display high binding affinity
and specificity for target molecules [32–34]. The affinity of
aptamers has been compared with that of antibodies (i.e. in the
nanomolar range), but as aptamers are smaller (8–25 kDa
compared to the 150 kDa size of antibodies), they can both
penetrate tissues and be cleared from the plasma within minutes of
intravenous administration without triggering an immune re-
sponse, which can be useful when using them as diagnostic agents
[35]. For therapeutic use, they are able to retain their function and
binding characteristics upon modification with other moieties to
improve their stability and solubility, whilst reducing their toxicity
and plasma clearance [35–38][39–41]. Typically, aptamers are
from 22 to 100 bases in length, and contain a region of variable
sequence, flanked by known sequences, which are used for
amplification and identification purposes. A large repertoire of
different sequence combinations (typically in the region of 1015) in
the central domain creates many different folding arrangements,
specificity and binding affinity for different molecules. Aptamers
are typically produced based on the SELEX (systematic evolution
of ligands by exponential enrichment) procedure [42], although a
number of other selection methodologies are currently available
[43–45].
Aptamers were previously generated against active human
recombinant heparanase using a modified SELEX protocol and
salt elution series. Selection yielded three aptamers, ‘1.5 M short’,
a 30 base truncated version of ‘1.5 M long’ (73 bases), and ‘3.0 M’
(55 bases). ELISAs and fluorescence titrations separated the two
longer aptamers as showing higher affinity and recognition of
heparanase in placental cells, whereas placental tissue staining
favoured ‘1.5 M long’. This was confirmed in a Matrigel invasion
assay using ovarian carcinoma cells previously shown to require
heparanase for invasion [46]. Two additional aptamers, termed
‘pink’ and ‘yellow’ were selected against the linker peptide
sequence of pro-heparanase, as these could have a function in
inhibiting the formation of the active heterodimer enzyme, by
blocking peptide protease excision.
In this study, efforts were made to further characterise the
previously selected aptamers and to assess their potential as a
diagnostic or therapeutic agent. The stability of the aptamer was
assessed by incubation over different time points with human and
mouse serum, and polyacrylamide gel electrophoresis used to
determine the extent of its degradation by nucleases present in the
serum. An additional invasion assay, in addition to the previous
mouse EHS-tumour derived Matrigel invasion assay, was carried
out using human uterine leiomyoma tissue and heparanase-
expressing human oral squamous carcinoma cells (HSC-3), as this
experiment represents a more authentic picture of what happens
in human tissue. Furthermore, a cell cytotoxicity/cell proliferation
assay was performed to verify that any inhibition of invasion
observed was not a result of cytotoxicity on the part of the
aptamers. Finally, the interactions of the aptamers with serum
proteins was investigated to both verify specificity of the aptamers
and study their potential transport by such proteins in the
bloodstream. Increasing literature in the DNA aptamer field has
demonstrated that these molecules have tremendous therapeutic
potential in cancer therapy treatment and have already been used
as so called escort molecules to deliver drugs into cancer cells
(reviewed in [47]). AS1411 is an example of a DNA aptamer that
has progressed to clinical trials testing. The aptamer in this case
specifically targets nucleolin protein and has been trialed with
metastatic, clear-cell, renal cell carcinoma patients who have been
refractory to prior tyrosine kinase inhibitors [48].
Materials and Methods
Cell culture
Human tongue squamous carcinoma cells, HSC-3 (JCRB 0623;
Osaka National Institute of Health Sciences, Osaka, Japan), were
cultured in growth media: 50% DMEM 50% Ham’s F-12 (Sigma
Aldrich) and additionally supplemented with 50 mg/ml ascorbic
acid, 250 ng/ml amphotericin B, 5mg/ml insulin (bovine pancre-
as), 0.4 ng/ml hydrocortisone and 10% heat-inactivated foetal
bovine serum. The culture supplement was purchased from Sigma
Aldrich. All cell cultures were carried out using pre-warmed
reagents. Cells were incubated in 95% air/5% CO2 at 37uC. Cells
were passaged by removing media and washing with HBSS (Sigma
Aldrich), then adding 3 ml 16 Trypsin-EDTA (Sigma Aldrich)
and incubating for 5 minutes. The Trypsin-EDTA was inactivated
by adding 7 ml growth media and removing any cell clumps. 1 ml
cell suspension (plus 24 ml fresh growth media) was retained in the
flask for maintenance of stocks and the remaining 9 ml was
counted and used for experiments.
Organotypic invasion assay and analyses of the inhibitors
on invasion
The organotypic invasion assay and the quantitation of results
were performed as described in Nurmenniemi et al. (2009) [49].
Briefly, 76 105 HSC-3 cells suspended in media containing the
appropriate aptamer (Unrelated, 1.5 M short, 1.5 M long, 3 M,
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Pink and Yellow) or an antibody against heparanase (Hpa Ab,
0.7 mM). Also (2-{4-[(E)-3-(4-bromophenyl) acryloylamino]-3-
fluorophenyl} benzooxazol-5-yl) acetic acid, abbreviated to BAFB,
was used, as this was shown to have inhibitory effects upon
heparanase in previous studies [29] (Table 1). Each aptamer or
antibody was added at 1 mM to HSC-3 cell suspension in the
beginning of the study and in the HSC-3 cell culture media
throughout the experiment. Myoma disks without HSC-3 cells and
HSC-3 cells without inhibitor were also included in the assay as
controls. The disks were incubated for 14 days at 37uC with 5%
CO2 with the media containing the appropriate inhibitors. The
media were collected, centrifuged, and fresh media with inhibitors
were changed at days 4, 7, 10 and 14. From the collected media
supernatants, the degradation products of myoma tissue type III
collagen were analyzed using SP99 radioimmunoassay (RIA) for
C-terminal telopeptide (IIICTP), and N-terminal telopeptide
(IIINTP) indirect enzyme immunoassays (EIA) for N-terminal
telopeptide, following the methods described in Nurmenniemi et
al. ([49] for RIA and [50] for EIA). On day 14, the myoma disks
were fixed in 4% paraformaldehyde and prepared for immuno-
histological analysis. Six mm histological sections of myoma disks
were stained with monoclonal pancytokeratin antibody (DAKO,
clone AE1/AE3 at a 1:150 dilution) and viewed under a
microscope at 100 6 magnification. Nine representative images
were taken from each of the three repeats of every treatment.
Images were analyzed as described in Nurmenniemi et al. (2009)
[49]. Differences in the invasion area and depth were evaluated
using a Student’s t-test and Mann-Whitney test and p-values less
than 0.05 were considered statistically significant.
Cell proliferation assay
To determine the effect of the ‘1.5 M short’ aptamer on HSC-3
cell proliferation, we used the CellTiter 96 AQueous Cell
Proliferation Assay (Promega), an MTS assay. Approximately 1
6 104 cells were seeded in triplicate for in a 96-well plate with
1mM of the short aptamer. After 24, 48 and 72 h, 20 ml of
CellTiter 96 Aqueous One Solution Reagent were added to each
well and cells were incubated for 1 h at 37uC in a 5% CO2
incubator. The absorbance recorded at 490 nm on a FLUOstar
Optima plate reader was used as a representation of the relative
number of living cells in culture.
Serum stability assay
Aptamers ‘1.5 M short’, ‘1.5 M long’ and ‘3.0 M’ were
incubated at a concentration of 5 mM with human and mouse
serum for 30, 60, 120, 180, 240 and 300 minutes at 37uC. The
reaction was then stopped by the addition of 100 mM EDTA and
the products ran on a 12% native polyacrylamide gel, alongside a
25 bp DNA marker ladder. Gels were stained using ethidium
bromide and viewed under UV light.
Serum albumin binding
Bovine Serum Albumin (BSA) was purchased from Sigma-
Aldrich Ltd (Gillingham, UK, product code A7030 10 g). UV
experiments were conducted on a Bio-Tek Uvikon XL with a
Peltier Thermosystem for temperature control and stirring facility,
connected to the PC utilizing Lab Power Junior software for data
collection and analysis. Fluorimeter used was a Horiba Jobin Yvon
Fluoromax-P equipped with a photon counter and Peltier system
for temperature control and stirring facility, coupled to a PC
utilizing Datamax software for spectral analysis. Initial measure-
ments were taken to verify the presence or absence of fluorescent
emission of both aptamers for excitation wavelength of 290 nm
(selective for tryptophan residues) and emission wavelengths
between 300 and 400 nm. Both aptamers were titrated in water
and 10 mM phosphate buffer solutions pH 7.4, at 37uC. The
1.5 M short aptamer concentration varied from 0.3 to 8.0 mM,
and the 1.5 M long aptamer varied from 0.5 to 8.0 mM, showing
the intrinsic fluorescence of these aptamers. Both aptamers
presented fluorescence emission spectra in this range. Earlier tests
showed that aptamer concentrations ranging from 0.1 mg/ml to
8 mg/ml did not interfere in the evaluation of albumin quenching
[51]. Quenching measurements were taken in 1 ml of 6 mM
albumins in phosphate buffer pH 7.4. Emission spectra were
registered from 300 to 400 nm wavelength, after a reaction time of
90 sec from each aptamer addition. Both emission and excitation
bandwidth were set to 3 nm. Aptamer was added from a
concentrated stock solution so that the volume increment was
negligible. Experiments were performed at 37uC, pH 7.4.
To evaluate any existing primary and/or secondary inner filter
effects (IFEs), correction procedures based on absorbance mea-
surements of solutions were performed at excitation and emission
wavelengths of albumin. This effect consists on the absorption of
exciting and/or emitted radiation by dissolved species, including
the fluorophore itself [52]. Absorbance measurement of aptamers/
albumin solutions at excitation and emission wavelengths of
albumin showed that inner filter effect caused by absorption of
emitted radiation was negligible.
Results
The anti-heparanase aptamers inhibit carcinoma cell
invasion
The invasion of HSC-3 cells was studied with a human myoma
organotypic model [49] exposing the carcinoma cells to various
aptamers (Unrelated, 1.5 M short, 1.5 M long, 3 M, Pink, and
Yellow) or heparanase antibody (Hpa Ab) (Fig. 1A). The effects of
these compounds compared to control (no inhibitor) on invasion
area (calculated based on the mm-area of invasive cells) and depth
of invasion (the distance from the lower surface of the noninvasive
cell layer to the deepest invaded cell) were analyzed (Fig. 1B and
C). Aptamer 1.5 M Short decreased significantly the total invasion
Table 1. The aptamer sequences used in this study.
Name Sequence
1.5 M Long GGGAGACAAGAATAAACGCTCAAATGG ACTTTTGAATGTGGCAACAAATTCGACAGG AGGCTCACAACAGGC
1.5 M Short ACTTTTGAATGTGGCAACAAATTCGACAGG
Pink TTGCTCCTTATAGAGCCGTCCGAGC
Yellow CTAAAGTGCCTCACGCTGTTAACTC
In bold the sequence of the short aptamer, which is the part of the long aptamer that is structured.
doi:10.1371/journal.pone.0096846.t001
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area (p = 0.0001) similar to Hpa Ab, which was used as a positive
invasion inhibitor control [27]. On the contrary, none of the other
compounds had an effect on HSC-3 invasion (Figure 1). The
invasion depth decreased significantly only after Hpa Ab
treatment (p = 0.0001) (Figure 1C). Based on our previous
findings, the degradation of type III collagen by HSC-3 cells
measured with RIA peaks from days 7 to 11 [49]. Similarly, the
media analyzed by RIA from day 4 did not show differences
between any of the treatments (not shown). The media change
upon termination of the experiment at day 14 showed only
statistical significance from the treatment with no cells added
(p = 0.001; not shown). Degradation of type III collagen without
inhibitors was highest at days 7 (not shown) and 10 (Figure 2A–D).
On day 10, the treatment with heparanase antibody inhibited
significantly the degradation compared to unrelated control
(p = 0.07 in RIA, and p = 0.03 in EIA). On day 10 there was a
significant inhibition by 1.5 M Short (p = 0.004 in RIA, and
p = 0.007 in EIA) and 1.5 M Long (p = 0.02 in RIA, and p = 0.03
in EIA) compared to HSC-3 control. However, 3 M, Pink, and
Yellow aptamers, as well as BAFB showed no significant decrease
in the amount of collagen degradation products, indicating that
they were not successful inhibitors of invasion.
The short anti-heparanase aptamer does not exhibit any
cytotoxicity
The cytotoxicity of the selected aptamers on HSC-3 cells was
studied, to verify that the inhibition of invasion observed in the
organotypic model was a result of the inhibition of the heparanase,
as previously verified [46] and not cell cytotoxicity. The MTS
assay was performed over 72 hrs, with a single addition of the
aptamer in the beginning of the assay, and measurements over the
period intervals of 24, 48 and 72 hrs. No change in cell viability
and cell growth was observed between the cells where aptamer was
added and the control (see Figure 3). Only the aptamers that
showed inhibition of invasion were tested for cytotoxicity, to
investigate if the inhibitory effect observed was due to cytotoxicity
or inhibition of heparanase. Aptamers that do not inhibit cell
invasion clearly have no effect on the cells and therefore there was
no reason to be further studied for cytotoxicity.
The short anti-heparanase aptamer does not bind
significantly to serum proteins
Short and long aptamers 1.5 M were initially titrated stepwise
into water and phosphate buffer solution, pH 7.4 at 37uC to
investigate their intrinsic fluorescence. Both aptamers have
intrinsic fluorescence with peaks at 380 nm, which increases in
Figure 1. HSC-3 invasion in myoma discs. A: Paraffin-embedded 14-day myoma organotypic sections were stained for pancytokeratin marker
AE1/AE3 to analyze HSC-3 invasion after various treatments: no inhibitor, Hpa Ab, (the polyclonal heparanase antibody as a positive control),
unrelated aptamer, (selected against a target involved in Alzheimer’s disease), anti-heparanase aptamers 1.5 M Short, 1.5 M long and 3 M; linker
peptide aptamers Pink and Yellow. Scale bar is 100 mm. The differences in invasion area (B) and invasion depth (C) after various treatments (n = 27/
treatment). The statistics were done as two-sample t-test and Mann-Whitney test.
doi:10.1371/journal.pone.0096846.g001
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fluorescence intensity upon a corresponding increase of the
aptamer concentration; the short showing less fluorescence than
the long aptamer (Figure 4A and B). Water was used as a diluent
to show that the aptamer and not phosphate buffer solution was
the cause of the fluorescence, although the fluorescence for the
short aptamer increased upon using phosphate buffer solution as
the diluent. However, this was likely due to a difference in pH as in
fluorescence spectroscopy pH changes have a significant influence
on results.
The short aptamer was able to quench the fluorescence of HSA
at 37uC by 1.5% (60.03%) and 9% (61.2%) at 1:100 and 1:10
molar ratios respectively, with quenching of 10% achieved by a
molar concentration 9.1 times lower than HSA (Figure 5). Long
aptamer is able to quench the fluorescence of HSA by 10% at a
concentration 18.2 times lower than HSA, and by 2.4% (60.1%)
and 16% (60.6%) at 1:100 and 1:10 molar ratios. The results
show that both aptamers are able to quench the fluorescence of
HSA, although the long aptamer was more effective. HSA
quenching indicates that the aptamers reach sub domain IIA,
where its single tryptophan is located. This tryptophan residue is
located at site 214 in subdomain IIA, within which there is a large
hydrophobic cavity with many arginine residues near the surface
[53], which have been shown in different studies to serve as anchor
points for aptamers [54].
To gain more information about the type of interaction
occurring between the aptamers and HSA, UV spectrometry
titrations were carried out by titrating increasing concentrations of
short and long aptamers and 6 mM HSA diluted in phosphate
buffer pH 7.4, as shown in Figure 5. The addition of both
aptamers to phosphate buffer and HSA increased the overall
absorbance, showing that the aptamer was responsible for this
increase rather than HSA. The increase was more pronounced for
the long aptamer over the short aptamer, and both produced a
shift of the maximum absorbance to the left upon addition of
increasing concentrations of aptamer.
The shift observed from the short aptamer (Figure 6A) moved
6 nm to the left, suggesting that only a slight conformational
change in the protein was occurring [55] and therefore, HSA
quenching by this aptamer is most likely due to dynamic
quenching. However, in the case of the long aptamer (Figure 6B),
not only was there a substantial shift in the maximal absorption by
20 nm to the left, but a complete change in the shape of the peak
Figure 2. EIA and RIA assays. A: EIA (IIINTP indirect enzyme immunoassays) detecting N-terminal telopeptide from collagen type III degradation
products at day 10 media change. Increasing absorbance means less collagen degradation product present. Hpa Ab (p = 0.03), 1.5 M Short (p = 0.007)
and 1.5 M Long (p = 0.03) showed significant increase in absorbance compared to no inhibitor, suggesting they have inhibited the invasion of HSC-3
cells. B: The graph shows previous EIA values adjusted for negative control at day 10 media change. C: RIA (radioimmunoassay for type III collagen)
detecting C-terminal telopeptide at day 10 media change. Increasing levels mean less collagen degradation product. Hpa Ab (p = 0.07), 1.5 M Short
(p = 0.004) and 1.5 M Long (p = 0.02). D: RIA has confirmed the EIA assays showing significantly lower collagen degradation products than that for
tissues without inhibitor added, indicating that they were successful inhibitors of invasion.
doi:10.1371/journal.pone.0096846.g002
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Figure 3. The MTS absorbance at 490 nm is shown over 24, 48 and 72 h in the presence and absence of the 1.5 M short aptamer.
The presence of the aptamer at 1 mM concentration was found to have no effect on the cell growth in comparison with the control.
doi:10.1371/journal.pone.0096846.g003
Figure 4. Fluorescence spectra of short aptamer in water and phosphate buffer solution (A) and PBS (B), at 376C. Fluorescence
increases upon increasing the concentration of aptamer in both phosphate and water, showing that although the fluorescence is higher in
phosphate, the aptamer is in fact the cause and the pH difference in water and PBS is the most likely reason for the increase of fluorescence of the
aptamer in PBS.
doi:10.1371/journal.pone.0096846.g004
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was observed, incorporating the peak at 260 nm of the aptamer,
suggesting that one complex was formed and that the quenching
was due to the static quenching phenomenon with long aptamers
[55]. Thus, the UV titrations suggested that the short aptamer did
not form a complex with HSA and that the interactions were due
to dynamic quenching, whereas the long aptamer was suggested to
form a ground state complex with HSA, in contrast with other
aptamers previously studied, which also show specificity and
complex formation only with their target protein [56]. This work
has been expanded and interactions of the aptamers with serum
proteins and the specific position of their interaction has been
calculated and published separately, as it was not within the scope
of this article [57].
Aptamers are stable in human serum
To assess the aptamers’ suitability as therapeutic agents, it was
necessary to have an understanding of how stable the unmodified
aptamers would be in the body, as, in the bloodstream alone, there
are many nucleases capable of degrading the aptamers. Thus, to
verify the stability of the aptamers in human serum, we have
characterized any degradation products by gel electrophoresis.
Comparison of bands on the gels for 1.5 M short aptamer
incubated for different time points with human and mouse serum,
with that of aptamer only showed that 1.5 M short aptamer was
not subject to nuclease degradation from human serum as the
bands did not show any smearing or decrease in size or intensity
compared to aptamer only, and hence, no breakdown of the
aptamer into smaller fragments was observed (data not shown).
With mouse serum, however, there was a decrease in primary
band intensity at five hours’ incubation time, suggesting that
nucleases have degraded the aptamer by that time.
Discussion
In this study we have explored the potential of previously
selected aptamers against heparanase as promising diagnostic and
therapeutic agents against oral cancer. The aptamers were
previously shown to have high affinity against heparanase and
were functional in a Matrigel assay. On these initial studies, it was
found that the longer aptamers had a higher affinity for
heparanase and they had performed well in fluorescent micros-
copy and Matrigel invasion assays. However, when we examined
these aptamers on the organotypic invasion assay and analysed
their potential to block invasion, it was found that the short
aptamer was far more capable of doing so, compared to its long
counterparts. This was also verified by the analysis by RIA and
EIA of the degradation products of myoma tissue, namely type III
collagen C- and N-terminal telopeptide respectively. The 1.5 M
Short and 1.5 M Long aptamers consist of the same variable
region and in fact the short one is a truncated version of the long.
However, it appears that although the long one has a slightly
higher affinity, probably due to increased interactions between the
protein and the primer parts of the aptamer, these resulted in
reducing the ability of these aptamers to inhibit tissue invasion.
The presence of various proteins in the actual tissue, as compared
to the Matrigel experiment previously performed, may be the
reason for this, as the long aptamer may form other interactions
with such proteins, or the primer tails may have a steric hindrance
effect on the tissue, which is not apparent in the simpler matrigel
model. This, in fact, was confirmed by the study of the interactions
between the two aptamers and serum proteins. In these studies it
was found that the long aptamer formed a complex with human
serum albumin, whereas the short aptamer did not form a
complex and showed only a limited dynamic quenching. In a
further study [57], we have modelled the interactions of the short
and long aptamers with HSA and have identified that indeed the
long aptamer forms a complex with serum albumins in a single
binding site, close to Trp 214 of HSA or 212 of BSA, at the
subdomain IIA of these proteins, in a positively charged cavity
lined with lysine and arginine residues [57]. It has been
demonstrated that the shorter aptamer species lacks the ability
to form complexes with serum proteins and exhibits thus higher
specificity for its target, which justifies our choice of using it in any
further therapeutic or diagnostic development and is in agreement
with the myoma data presented in this work. One further
important feature of this study is the demonstration that post-
SELEX modifications may be more beneficial for aptamer
selection than initial counter-selection steps, where this is possible.
In a series of studies with various methodologies of detection,
aptamer affinity for their target has been compared to that for
albumin. The majority of the exemplars for new aptamer-based
detection methodologies are based on the thrombin aptamers. In a
study of aptamer-enhanced laser desorption/ionization study, the
thrombin-binding DNA aptamer was used for affinity capture of
thrombin in MALDI-TOF-MS. This aptamer was shown to be
capable to bind to thrombin in a thrombin/albumin mixture [58].
Similarly, aptamers have been shown to distinguish thrombin from
albumin in a QCM experiment [59]. Another G-quadruplex
based thrombin aptamer in cationic polythiophene protein
detection arrays was also able to detect thrombin over albumin
in the attomole range in less than one hour without any tagging of
the target [60]. The thrombin aptamer has also been used in an
electrochemical detection assay, where it has been able to separate
thrombin from BSA, HSA, Lysozyme and immunoglobulin G
[61].
Apart from the thrombin aptamers, other aptamers in detection
assays have also been compared with albumin, or have shown
specific binding in the presence of high concentration of albumins.
In an electrochemical sensor, aptamers against lysozyme have
been shown to detect lysozyme in a mixture of six proteins
Figure 5. Stern-Volmer plots for HSA titrated by short and long
apatmers 376C. Excitation wavelength 290 nm, [HSA] = 6 mM.
Excitation wavelength at 290 mM in a solution of sodium phosphate.
Data is the mean of six values showing no greater standard deviation
than 11%. The quenching effect is more considerable for long than
short aptamer.
doi:10.1371/journal.pone.0096846.g005
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including albumin [62]. Immunoglobulin E has also been detected
in serum over albumin [63], whereas an anti- F. tularensis
aptamer cocktail, when tested in a sandwich Aptamer-Linked
Immobilized Sorbent Assay (ALISA) and dot blot analysis,
exhibited specificity in its ability to bind only to tularemia
bacterial antigen from subspecies japonica, holarctica (also known
as palaearctica) and tularensis but not to Bartonella henselae, nor
to pure chicken albumin or chicken lysozyme, demonstrating the
ability of this aptamer cocktail to function as a bacterial detection
agent [64].
Depending on the aptamer species, some aptamers present
cross-reactivity with serum albumins, whereas the majority of
them are capable of distinguishing between the protein they have
been selected for, and albumins. Thus, for example, when we
investigated a number of KLK6 aptamers with serum albumins,
we identified that the majority of the selected aptamers against
that target were specific, but one of them had significant affinity
for albumin [65]. In addition, it is important to note that the same
aptamer may or may not form complexes with HSA or BSA,
depending on their post-SELEX refinement. Thus, the heparanase
aptamer of this study, when truncated for the binding site of the
specific target protein, does not form a stable complex with serum
proteins, whereas its longer counterpart that contains the flanking
primers, not selected for specific binding, can do. This is important
Figure 6. UV wavelength scan of HSA (left) and plot of PBS (right) titrated with 1.5 M short aptamer (A) and UV wavelength scan of
HSA (left) and plot of PBS (right) titrated with 1.5 M long aptamer (B).
doi:10.1371/journal.pone.0096846.g006
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with respect to selection strategies, as, in the case of heparanase,
we started the selection with a naı¨ve library, containing all possible
species, and the selection and studies clearly indicated that one
aptamer species was the best candidate. This candidate would
have been lost if a counter-selection against albumins had been
performed at the beginning, as it also presents affinity for these
proteins prior to truncation. However, with a simple truncation of
the flanking primers, the aptamer gained the necessary specificity
to be further developed for therapeutic and diagnostic applica-
tions.
Furthermore, the effect seen in the inhibition of the invasion
assay could have been a result of a cytotoxic effect on the part of
aptamers. This possibility was eliminated in a cytotoxicity assay,
which clearly demonstrated that the aptamers did not show any
cytotoxic effect on these cells after 72 hours of incubation, thus
verifying that the inhibition of invasion was in fact due to
inhibition of heparanase. Finally, aptamers were found to be stable
in human serum even without any modification, making them
potentially interesting therapeutic reagents on their own accord.
This is important as such stability would reduce production costs
of such an aptamer, if it were selected for subsequent therapeutic
or diagnostic applications.
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